April 30, 2019

Neil Kumar, Ph.D.
Chief Executive Officer
BridgeBio Pharma LLC
421 Kipling Street
Palo Alto, CA 94301

       Re: BridgeBio Pharma LLC
           Amendment No. 1 to Draft Registration Statement on Form S-1
           Submitted on April 16, 2019
           CIK No. 0001743881

Dear Dr. Kumar:

      We have reviewed your amended draft registration statement and have the
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional

Amendment No. 1 to Draft Registration Statement on Form S-1

Prospectus Summary
Our Platform, page 2

1.     We note your revisions in response to our prior comment 2. Please
       revise statements in your prospectus that imply you will be successful
in mitigating risk
       associated with drug development. We note, for example, your statement
on page 2 that
       you pursue programs with validated treatment modalities, which you
believe allows you to
       avoid the increased risk associated with less tested approaches. Please
revise your
       disclosure throughout to remove the suggestion that your drug candidates
are part of
       validated treatment modalities and that you can lessen the risks of drug
 Neil Kumar, Ph.D.
FirstName Pharma LLC Kumar, Ph.D.
BridgeBio LastNameNeil
Comapany NameBridgeBio Pharma LLC
April 30, 2019
April 2 2019 Page 2
Page 30,
FirstName LastName

Our Investment Thesis, page 4

2.       We note your response to comment 9 and continue to view these
statements as
         inappropriate. As you have not yet successfully commercialized any
product candidates or
         translated a "pool" of "innovation" into "life-changing medicines,"
this discussion does
         not appear appropriately tailored to your business. In addition, the
fact that your business
         is subject to short-term variance and you manage your business by
focusing on long-term
         decisions does not appear to be unique. Please revise this disclosure
to present balanced,
         factual information related to your business plan, or remove this
disclosure. Please also
         tell us why you believe the company's business model represents a "new
type of
         company" and provide support for your statement on page 1 that your
focus on early-stage
         development is "often-overlooked" as well as your statement on page 3
that other
         companies have "excess overhead" which you have been able to
Our Pipeline, page 4

3.       We note your response to comment 7 and the footnote disclosure to your
pipeline chart.
         We do not agree that your use of the term "registrational" is
appropriate due to the
         uncertainty. Please remove such references to "registrational" trials
here and throughout
         your registration statement.
Management's Discussion and Analysis of Financial Condition and Results of
Basis of Presentation and Consolidation, page 96

4.       Please clarify how the 52.1% ownership interest in PellePharm, Inc. at
December 31, 2018
         was calculated. In this regard, we note that at the date of
deconsolidation in November
         2018 you owned an 8% common stock interest and a 61.9% preferred stock
interest in
         PellePharm, Inc.
BBP-831/Infigratinib (QED): FGFR-Driven Cancers
Clinical Development Plans , page 139

5.       We note your response to comment 19, which we reissue in part. Please
expand your
         disclosure to disclose the impact to approval and/or marketing of
infigratinib in the event
         your companion diagnostic is not approved.
BBP-009/Patidegib (PellePharm): Gorlin Syndrome and High Frequency Basal Cell
Clinical Data, page 157

6.       We note your response to comment 22. Please expand your disclosure to
define the term
         "complete clinical response" in this context.
 Neil Kumar, Ph.D.
BridgeBio Pharma LLC
April 30, 2019
Page 3

Notes to Combined and Consolidated Financial Statements
7. Noncontrolling Interests , page F-32

7.    Please provide your analysis supporting the amounts recorded in the
      adjustment due to change in ownership during 2018. Please tell us the
basis for the
      adjustments and cite the applicable GAAP guidance.
       You may contact Rolf Sundwall at 202-551-3105 or Mary Mast at
202-551-3613 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Christine Westbrook at 202-551-5019 or Erin Jaskot at 202-551-3442 with
any other

FirstName LastNameNeil Kumar, Ph.D.
                                                           Division of
Corporation Finance
Comapany NameBridgeBio Pharma LLC
                                                           Office of Healthcare
& Insurance
April 30, 2019 Page 3
cc:       Maggie Wong, Esq.
FirstName LastName